EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Plasma DNA Methylation‐Based Biomarkers for MPNST Detection in Patients With Neurofibromatosis Type 1

Katarzyna Tomczak iD, Manishkumar S Patel iD, Angela D Bhalla iD, Christine B Peterson iD, Sharon M Landers iD, S Carson Callahan iD, Di Zhang, Justin Wong iD, Jace P Landry iD, Alexander J Lazar iD, J Andrew Livingston iD, B Ashleigh Guadagnolo iD und 13 weitere

Molecular Carcinogenesis · 2025

DOI: 10.1002/mc.23825 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Carcinogenesis, 2025. Verfasst von Katarzyna Tomczak und 24 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Hauptthemen laut MEDLINE: DNA Methylation, Neurofibromatosis 1, Biomarkers, Tumor, CpG Islands. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, This work was partially supported by The Texas Neurofibromatosis Foundation, the Sally M. Kingsbury Sarcoma Research Foundation, A Shelter for Cancer Families,….

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Malignant peripheral nerve sheath tumor (MPNST) development is characterized by an altered DNA methylation landscape, which presents a promising area for developing MPNST‐specific biomarkers for screening patients with NF1. Genome‐wide DNA methylation profiling of a cohort of 13 patients with MPNST (29 samples of tumor and adjacent neurofibroma tissues) and of NF1‐MPNST cell lines was performed to identify and validate candidate MPNST‐specific CpG sites (CpGs). A logistic regression prediction model was constructed to select MPNST‐specific CpGs distinct from adjacent neurofibromas and normal tissues. To test if hypermethylation at selected CpGs can also be detected in plasma from patients with MPNST, cfMBD‐seq was applied to profile the cfDNA methylome of blood from patients with MPNST and NF1. Based on stringent feature‐selection criteria and predictive modeling, we identified 73 candidate MPNST‐specific CpGs (67 with unique CpG island locations) that reliably discriminated MPNSTs from neurofibromas. Validation of five candidate biomarkers confirmed successful MPNST detection (sensitivity: > 88%, specificity: > 91%) in tissues. In plasma samples, 63 of 67 selected genomic regions had greater than 1.2‐fold higher methylation in patients with MPNST than those with NF1. Further, we identified 15 CpG islands that consistently separated plasma from patients with confirmed MPNST diagnosis from plasma of individuals with NF1 without a diagnosis of malignant transformation (FDR < 0.1). Our findings confirmed a unique hypermethylation pattern present during malignant transformation. This study highlights the potential to be investigated further as biomarkers in clinical settings for early MPNST detection in patients with NF1.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DNA MethylationNeurofibromatosis 1Biomarkers, TumorCpG IslandsHumansFemaleMaleAdultMiddle AgedNeurofibrosarcomaCell Line, TumorAged

Stichwörter der Autor:innen

DNA methylationMPNSTbiomarkerneurofibromatosis type 1plasma

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Department of Tumor Microenvironment and Metastasis, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA.
  • Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

ORCID-Profile: Katarzyna Tomczak, Manishkumar S Patel, Angela D Bhalla, Christine B Peterson, Sharon M Landers, S Carson Callahan, Justin Wong, Jace P Landry, Alexander J Lazar, J Andrew Livingston, B Ashleigh Guadagnolo, Heather G Lyu, Heather Lillemoe, Christina L Roland, Emily Z Keung, Kelly K Hunt, Ian E McCutcheon, John M Slopis, Jian Gu, Paul Scheet, Liang Wang, Kunal Rai, Keila E Torres

Förderung

  • NCI NIH HHS
  • This work was partially supported by The Texas Neurofibromatosis Foundation, the Sally M. Kingsbury Sarcoma Research Foundation, A Shelter for Cancer Families,…

Zitieren

APA

Tomczak, K., Patel, M. S., Bhalla, A. D., Peterson, C. B., Landers, S. M., Callahan, S. C., Zhang, D., Wong, J., Landry, J. P., Lazar, A. J., Livingston, J. A., Guadagnolo, B. A., Lyu, H. G., Lillemoe, H., Roland, C. L., Keung, E. Z., Scally, C. P., Hunt, K. K., McCutcheon, I. E., …, & Torres, K. E. (2025). Plasma DNA Methylation‐Based Biomarkers for MPNST Detection in Patients With Neurofibromatosis Type 1. Molecular Carcinogenesis. https://doi.org/10.1002/mc.23825

Vancouver

Tomczak K, Patel MS, Bhalla AD, Peterson CB, Landers SM, Callahan SC, et al. Plasma DNA Methylation‐Based Biomarkers for MPNST Detection in Patients With Neurofibromatosis Type 1. Molecular Carcinogenesis. 2025. doi:10.1002/mc.23825

BibTeX
@article{Tomczak2025,
  author = {Tomczak, Katarzyna and Patel, Manishkumar S and Bhalla, Angela D and Peterson, Christine B and Landers, Sharon M and Callahan, S Carson and Zhang, Di and Wong, Justin and Landry, Jace P and Lazar, Alexander J and Livingston, J Andrew and Guadagnolo, B Ashleigh and Lyu, Heather G and Lillemoe, Heather and Roland, Christina L and Keung, Emily Z and Scally, Christopher P and Hunt, Kelly K and McCutcheon, Ian E and Slopis, John M and Gu, Jian and Scheet, Paul and Wang, Liang and Rai, Kunal and Torres, Keila E},
  title = {Plasma DNA Methylation‐Based Biomarkers for MPNST Detection in Patients With Neurofibromatosis Type 1},
  journal = {Molecular Carcinogenesis},
  year = {2025},
  doi = {10.1002/mc.23825}
}
Kostenlos starten →